DE102005048897A1 - Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen - Google Patents

Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen Download PDF

Info

Publication number
DE102005048897A1
DE102005048897A1 DE102005048897A DE102005048897A DE102005048897A1 DE 102005048897 A1 DE102005048897 A1 DE 102005048897A1 DE 102005048897 A DE102005048897 A DE 102005048897A DE 102005048897 A DE102005048897 A DE 102005048897A DE 102005048897 A1 DE102005048897 A1 DE 102005048897A1
Authority
DE
Germany
Prior art keywords
alkyl
compounds
formulas
heterocycle
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102005048897A
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37813518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE102005048897(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to DE102005048897A priority Critical patent/DE102005048897A1/de
Priority to BRPI0617222-9A priority patent/BRPI0617222A2/pt
Priority to AU2006301591A priority patent/AU2006301591A1/en
Priority to PCT/EP2006/009577 priority patent/WO2007042178A1/de
Priority to EP06806017.7A priority patent/EP1937648B1/de
Priority to JP2008534900A priority patent/JP2009511517A/ja
Priority to KR1020087008736A priority patent/KR20080048062A/ko
Priority to RU2008114360/04A priority patent/RU2008114360A/ru
Priority to CA002625546A priority patent/CA2625546A1/en
Priority to CNA2006800376850A priority patent/CN101282939A/zh
Priority to TW095136995A priority patent/TW200728285A/zh
Priority to ARP060104444A priority patent/AR056686A1/es
Priority to UY29853A priority patent/UY29853A1/es
Publication of DE102005048897A1 publication Critical patent/DE102005048897A1/de
Priority to ZA200802105A priority patent/ZA200802105B/xx
Priority to IL190672A priority patent/IL190672A0/en
Priority to MA30823A priority patent/MA29856B1/fr
Priority to US12/099,337 priority patent/US7772268B2/en
Priority to NO20081878A priority patent/NO20081878L/no
Priority to US12/839,863 priority patent/US8357698B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE102005048897A 2005-10-12 2005-10-12 Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen Withdrawn DE102005048897A1 (de)

Priority Applications (19)

Application Number Priority Date Filing Date Title
DE102005048897A DE102005048897A1 (de) 2005-10-12 2005-10-12 Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen
AU2006301591A AU2006301591A1 (en) 2005-10-12 2006-10-04 Diacyl indazol derivatives as lipase and phospholipase inhibitors
CA002625546A CA2625546A1 (en) 2005-10-12 2006-10-04 Diacyl indazol derivatives as lipase and phospholipase inhibitors
CNA2006800376850A CN101282939A (zh) 2005-10-12 2006-10-04 作为脂肪酶和磷脂酶抑制剂的二酰基吲唑衍生物
PCT/EP2006/009577 WO2007042178A1 (de) 2005-10-12 2006-10-04 Diacylindazol-derivate als inhibitoren von lipasen und phospholipasen
EP06806017.7A EP1937648B1 (de) 2005-10-12 2006-10-04 Diacylindazol-derivate als inhibitoren von lipasen und phospholipasen
JP2008534900A JP2009511517A (ja) 2005-10-12 2006-10-04 リパーゼおよびホスホリパーゼのインヒビターとしてのジアシルインダゾール誘導体
KR1020087008736A KR20080048062A (ko) 2005-10-12 2006-10-04 리파제 및 포스포리파제 억제제로서 디아실 인다졸 유도체
RU2008114360/04A RU2008114360A (ru) 2005-10-12 2006-10-04 Производные диацилиндазола как ингибиторы липаз и фосфолипаз
BRPI0617222-9A BRPI0617222A2 (pt) 2005-10-12 2006-10-04 derivados de diacilindazol como inibidores de lipase e fosfolipase
TW095136995A TW200728285A (en) 2005-10-12 2006-10-05 Diacylindazole derivatives as inhibitors of lipases and phospholipases
ARP060104444A AR056686A1 (es) 2005-10-12 2006-10-10 Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas
UY29853A UY29853A1 (es) 2005-10-12 2006-10-11 Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
ZA200802105A ZA200802105B (en) 2005-10-12 2008-03-06 Diacyl indazol derivatives as lipase and phospholipase inhibitors
IL190672A IL190672A0 (en) 2005-10-12 2008-04-07 Diacyl indazol derivatives as lipase and phospholipase inhibitors
MA30823A MA29856B1 (fr) 2005-10-12 2008-04-08 Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
US12/099,337 US7772268B2 (en) 2005-10-12 2008-04-08 Diacyl indazole derivatives as lipase and phospholipase inhibitors
NO20081878A NO20081878L (no) 2005-10-12 2008-04-18 Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
US12/839,863 US8357698B2 (en) 2005-10-12 2010-07-20 Diacyl indazole derivatives as lipase and phospholipase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005048897A DE102005048897A1 (de) 2005-10-12 2005-10-12 Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen

Publications (1)

Publication Number Publication Date
DE102005048897A1 true DE102005048897A1 (de) 2007-04-19

Family

ID=37813518

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102005048897A Withdrawn DE102005048897A1 (de) 2005-10-12 2005-10-12 Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen

Country Status (18)

Country Link
US (2) US7772268B2 (https=)
EP (1) EP1937648B1 (https=)
JP (1) JP2009511517A (https=)
KR (1) KR20080048062A (https=)
CN (1) CN101282939A (https=)
AR (1) AR056686A1 (https=)
AU (1) AU2006301591A1 (https=)
BR (1) BRPI0617222A2 (https=)
CA (1) CA2625546A1 (https=)
DE (1) DE102005048897A1 (https=)
IL (1) IL190672A0 (https=)
MA (1) MA29856B1 (https=)
NO (1) NO20081878L (https=)
RU (1) RU2008114360A (https=)
TW (1) TW200728285A (https=)
UY (1) UY29853A1 (https=)
WO (1) WO2007042178A1 (https=)
ZA (1) ZA200802105B (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2002835A1 (en) * 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
KR20110060901A (ko) * 2008-09-23 2011-06-08 겐쿄텍스 에스에이 Ｎａｄｐｈ 옥시다아제 억제제로서 피라졸로 피리딘 유도체
US8288432B2 (en) 2007-03-28 2012-10-16 Genkyotex Sa Tetrahydroindole derivatives as NADPH oxidase inhibitors
US8455485B2 (en) 2008-09-23 2013-06-04 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8481562B2 (en) 2008-09-23 2013-07-09 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US9096588B2 (en) 2008-09-23 2015-08-04 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US9394306B2 (en) 2009-09-28 2016-07-19 Genkyotex Sa Pyrazoline dione derivatives as NADPH oxidase inhibitors
US12011436B2 (en) 2017-11-01 2024-06-18 Calliditas Therapeutics Suisse Sa Use of NOX inhibitors for treatment of cancer
USRE50878E1 (en) 2008-09-23 2026-05-05 Calliditas Therapeutics Suisse Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200924762A (en) 2007-11-02 2009-06-16 Vertex Pharma Kinase inhibitors
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
US8957219B2 (en) 2008-10-17 2015-02-17 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on endothelial lipase
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
KR20120123325A (ko) 2009-12-15 2012-11-08 시오노기세야쿠 가부시키가이샤 혈관 내피 리파아제 저해 활성을 갖는 옥사디아졸 유도체
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
GB2497476B (en) * 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760828B1 (en) 2011-09-27 2015-10-21 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
EP2760829B1 (en) 2011-09-27 2016-05-18 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013048930A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
EP2760840B1 (en) 2011-09-30 2015-08-12 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
WO2013049104A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
EP2844643B1 (en) 2012-04-03 2016-11-30 Bristol-Myers Squibb Company Pyrimidinedione carboxamide inhibitors of endothelial lipase
US9394260B2 (en) 2012-04-03 2016-07-19 Bristol-Myers Squibb Company Pyrimidinone carboxamide inhibitors of endothelial lipase
AR092854A1 (es) 2012-07-09 2015-05-06 Bristol Myers Squibb Co Benzotiazoles que contienen sulfonilo como inhibidores de la lipasa endotelial
US9139578B2 (en) 2012-07-09 2015-09-22 Bristol-Myers Squibb Company Amide or urea containing benzothiazole inhibitors of endothelial lipase
WO2014015088A1 (en) 2012-07-19 2014-01-23 Bristol-Myers Squibb Company Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase
WO2014042939A1 (en) 2012-09-11 2014-03-20 Bristol-Myers Squibb Company Ketone linked benzothiazole inhibitors of endothelial lipase
US10173991B2 (en) 2014-01-07 2019-01-08 Bristol-Myers Squibb Company Sulfone amide linked benzothiazole inhibitors of endothelial lipase
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
US10597370B2 (en) 2016-06-06 2020-03-24 Bristol-Myers Squibb Company 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors
CN110526898A (zh) * 2018-05-25 2019-12-03 北京诺诚健华医药科技有限公司 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372421B1 (en) * 2000-06-13 2002-04-16 Eastman Kodak Company Photothermographic imaging element having improved contrast and methods of image formation
US7666867B2 (en) * 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
DE10247680B4 (de) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
AU2003286711A1 (en) * 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
DE602004023062D1 (en) * 2003-03-31 2009-10-22 Lilly Co Eli 3-oxo-1,3-dihydro-indazol-2-carbonsäureamid derivate als phospholipase inhibitoren
DE102004005172A1 (de) * 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Capuano, L., Braun, F., Lorenz, J. Zander, R. Bender, J. Liebigs Ann. Chem. 1981, 1361-1366 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073919B2 (en) 2007-03-22 2015-07-07 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8389518B2 (en) 2007-03-22 2013-03-05 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8288432B2 (en) 2007-03-28 2012-10-16 Genkyotex Sa Tetrahydroindole derivatives as NADPH oxidase inhibitors
EP2002835A1 (en) * 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US9006238B2 (en) 2008-09-23 2015-04-14 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US9096588B2 (en) 2008-09-23 2015-08-04 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8481562B2 (en) 2008-09-23 2013-07-09 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8940760B2 (en) 2008-09-23 2015-01-27 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8455485B2 (en) 2008-09-23 2013-06-04 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US9012449B2 (en) 2008-09-23 2015-04-21 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
KR20110060901A (ko) * 2008-09-23 2011-06-08 겐쿄텍스 에스에이 Ｎａｄｐｈ 옥시다아제 억제제로서 피라졸로 피리딘 유도체
US8455486B2 (en) 2008-09-23 2013-06-04 Genkyotex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
USRE50878E1 (en) 2008-09-23 2026-05-05 Calliditas Therapeutics Suisse Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
KR101716511B1 (ko) 2008-09-23 2017-03-14 겐쿄텍스 에스에이 Ｎａｄｐｈ 옥시다아제 억제제로서 피라졸로 피리딘 유도체
US9974791B2 (en) 2008-09-23 2018-05-22 Genkyotex Suisse Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US10772891B2 (en) 2008-09-23 2020-09-15 Genkyotex Suisse Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US9394306B2 (en) 2009-09-28 2016-07-19 Genkyotex Sa Pyrazoline dione derivatives as NADPH oxidase inhibitors
US12011436B2 (en) 2017-11-01 2024-06-18 Calliditas Therapeutics Suisse Sa Use of NOX inhibitors for treatment of cancer

Also Published As

Publication number Publication date
KR20080048062A (ko) 2008-05-30
AU2006301591A1 (en) 2007-04-19
US8357698B2 (en) 2013-01-22
ZA200802105B (en) 2009-09-30
AR056686A1 (es) 2007-10-17
EP1937648B1 (de) 2014-11-26
JP2009511517A (ja) 2009-03-19
CA2625546A1 (en) 2007-04-19
WO2007042178A1 (de) 2007-04-19
US20080287448A1 (en) 2008-11-20
MA29856B1 (fr) 2008-10-03
US7772268B2 (en) 2010-08-10
UY29853A1 (es) 2007-05-31
TW200728285A (en) 2007-08-01
US20100286133A1 (en) 2010-11-11
RU2008114360A (ru) 2009-10-20
IL190672A0 (en) 2008-11-03
NO20081878L (no) 2008-04-18
EP1937648A1 (de) 2008-07-02
BRPI0617222A2 (pt) 2011-07-19
CN101282939A (zh) 2008-10-08

Similar Documents

Publication Publication Date Title
DE102005048897A1 (de) Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen
EP1713779B1 (de) Indazolderivate als inhibitoren der hormon-sensitiven lipase
DE102005049954A1 (de) Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
DE102005018389A1 (de) Azolderivate als Inhibitoren von Lipasen und Phospholipasen
DE102006014688A1 (de) Azolopyridin-3-on-derivate als Inhibitoren von Lipasen und Phospholipasen
DE102006014685A1 (de) Imidazo-pyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholiphasen
US7846943B2 (en) Azolopyridin-2-one derivatives as lipase and phospholipase inhibitors
DE102005049953A1 (de) Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
US20100173961A1 (en) Benzooxazol-2-one derivatives as lipase and phospholipase inhibitors
US8008331B2 (en) Benzothiazol-2-one derivatives as lipase and phospholipase inhibitors

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8127 New person/name/address of the applicant

Owner name: SANOFI-AVENTIS, PARIS, FR

R120 Application withdrawn or ip right abandoned

Effective date: 20110708